Osteoporosis

Shin DE et al. Clinic Rev Bone Miner Metab 2018; Advance online publication. doi: 10.1007/s12018-018-9245-0

Vellucci R et al. Osteoporos Int 2018; Advance online publication. doi: 10.1007/s00198-018-4476-y

Patients with glucocorticoid-induced osteoporosis who are treated with denosumab have greater improvements in bone mineral density than those treated with risedronate, phase III trial results suggest.

Levin VA, Jiang X, Kagan R. Osteoporos Int 2018; Advance online publication. doi: 10.1007/s00198-018-4414-z

The authors report the case of a 24-year-old woman diagnosed with glucocorticoid-induced osteoporosis in which initial treatment with teriparatide followed by treatment of kyphosis with correction fusion achieved a favorable outcome.

Uei H et al. Osteoporos Int 2018; Advance online publication. doi: 10.1007/s00198-018-4425-9

Anagnostis P et al. Endocrine 2018; Advance online publication. doi: 10.1007/s12020-018-1548-x

Bergman J, Nordström A, Nordström P. Osteoporos Int 2018; Advance online publication. doi: 10.1007/s00198-017-4367-7

The authors provide an overview of the new drugs on the horizon, abaloparatide and romosozumab, which stimulate bone formation, and therefore improve bone mass, structure, and ultimately skeletal strength.2

Minisola S, Cipriani C, Occhiuto M, Pepe J. Intern Emerg Med 2017. doi:10.1007/s11739-017-1719-4

In this review, the authors summarize recent literature addressing the risk factors, evaluation, and treatment for early bone fragility in patients with osteoporosis.

Grover M, Bachrach LK. Curr Osteoporos Rep 2017;15:271–282. doi:10.1007/s11914-017-0371-2

In this article, the authors briefly review the molecular mechanisms that lead to structural damage in ankylosing spondylitis and the impact of treatment with biologics to retard this process.

Magrey MN, Khan MA. Curr Rheumatol Rep 2017;19:17. doi:10.1007/s11926-017-0644-x

This review summarizes the evidence on using of osteoporosis drugs in combination and, with the exception of adding teriparatide to denosumab, finds little data to support using more than one drug at a time.

McClung MR. Curr Osteoporos Rep 2017;15:343–352. doi:10.1007/s11914-017-0376-x

This retrospective analysis found that denosumab significantly improved trabecular bone score independently of bone mineral density in postmenopausal women with osteoporosis.

McClung MR, Lippuner K, Brandi ML et al. Osteoporos Int 2017. doi:10.1007/s00198-017-4140-y

Heinlen & Humphrey review the clinical evidence for abnormal skeletal health in patients with rheumatoid arthritis and the effects of disease modifying anti-rheumatic drugs on bone health.

Heinlen L, Humphrey MB. Osteoporos Int 2017. doi:10.1007/s00198-017-4170-5

This review covers the recent advances in osteoporosis, including: Patient education, atypical femur fractures, vitamin supplementation, medication advances, post-fracture management, and screening/diagnostic modalities.

Schweser KM, Crist BD. Curr Rev Musculoskelet Med 2017;10:265–274. doi:10.1007/s12178-017-9410-y

The authors provide an overview of transient osteoporosis of the hip, covering the epidemiology, pathophysiology, etiology, diagnosis, treatment, and potential complications of the condition.1

Asadipooya K, Graves L, Greene LW. Osteoporos Int 2017;28:1805–1816. doi:10.1007/s00198-017-3952-0

This guideline, accredited by the National Institute of Health and Care Excellence, provides an overview of the assessment and management of osteoporosis for all healthcare professionals who are involved in its management.

Compston J, Cooper A, Cooper C et al. Arch Osteoporos 2017;12:43. doi:10.1007/s11657-017-0324-5

The authors review the effect of denosumab on osteoarticular erosive lesions in rheumatoid arthritis and study the potential effects of denosumab on disease activity, joint space narrowing, functional capacity, and safety.

Boleto G, Dramé M, Lambrecht I, Eschard JP, Salmon JH. Clin Rheumatol 2017;36:1699–1706. doi:10.1007/s10067-017-3722-6

This case report describes a 38-year-old woman, who presented with bilateral femoral stress fractures and osteoporosis after years of excessive levothyroxine treatment. How would you respond when presented with such a patient?

Laine CM, K. Landin-Wilhelmsen K. Osteoporos Int 2017; 28: 2247–2250. doi:10.1007/s00198-017-3981-8

This article reviews the efficacy and optimal use of parathyroid hormone and parathyroid hormone-related protein analogs in osteoporosis treatment.

Leder BZ. Curr Osteoporos Rep 2017;15:110–119. doi:10.1007/s11914-017-0353-4

Osteoporosis is increasingly recognized in children due to the increased prevalence of disorders associated with bone loss. This review explores diagnosis and treatment considerations in this population.

Marrani E et al. Drugs 2017;77:679–695. doi:10.1007/s40265-017-0715-3